Schwazze (SHWZ) AI Stock Analysis

• Market Cap: $78.00
• Dividend Yield: N/A
• Average Volume (3M): 15.75K
• Price to Earnings (P/E): ―
• Beta (1Y): -955.08
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 729
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 78,248,390
• 10 Day Avg. Volume: 31,966
• 30 Day Avg. Volume: 15,754
• PEG Ratio: 0.05
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.23
• P/FCF Ratio: 24.82
• Enterprise Value/Market Cap: 2.79M
• Enterprise Value/Revenue: 1.24
• Enterprise Value/Gross Profit: 3.86
• Enterprise Value/Ebitda: 14.35
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ―

Medicine Man Technologies faces considerable financial and operational risks, with weak profitability and high leverage. Technical indicators suggest bearish momentum, and valuation metrics highlight a lack of attractiveness. Corporate events add further uncertainty. The new leadership might bring positive change, but significant challenges need addressing.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market presence and product demand, supporting long-term business sustainability.

Positive Operating Cash Flows

Positive operating cash flows suggest effective cash management, providing the company with resources to invest in growth opportunities.

Leadership Change

New leadership with executive experience may bring strategic stability and enhance the company's position amid financial challenges.

Negative Factors

High Leverage

High leverage can strain financial resources and limit flexibility, posing risks to long-term financial health and stability.

Profitability Challenges

Persistent profitability issues indicate operational inefficiencies, potentially hindering the company's ability to sustain growth.

Notice of Default

The notice of default highlights significant financial and operational risks, which could impact the company's reputation and stability.

Schwazze Business Overview & Revenue Model

Company Description

Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. It operates through three segments: Retail, Wholesale, and Other. The company offers cannabis products that include loose flower, concentrates, edibles, pre-rolls, topicals, and other associated cannabis products; and vape cartridges and syringes. As of March 14, 2022, it owned and operated 23 retail cannabis dispensaries under the Star Buds, Smoking Gun Apothecary, Emerald Fields, and Drift banner names in Denver and Colorado; and 10 medical retail cannabis dispensaries under the R. Greenleaf banner in New Mexico. The company also provides licensing and consulting, facility design, and facility management services; and Three A Light publication. In addition, it manufactures, wholesales, and retails various plant nutrients for cannabis; and supplies hydroponics and indoor gardening supplies. The company was incorporated in 2014 and is headquartered in Denver, Colorado.

How the Company Makes Money

Medicine Man Technologies generates revenue through multiple channels within the cannabis industry. Its primary revenue streams include the sale of cannabis products through its retail dispensaries and wholesale distribution. The company also earns income from its cultivation operations, which supply high-quality cannabis to its own retail outlets and third-party dispensaries. Additionally, Schwazze benefits from its manufacturing and processing capabilities, producing value-added products such as concentrates and edibles. The company has established strategic partnerships and acquisitions to expand its market presence and enhance its product offerings, further contributing to its revenue growth. Regulatory compliance and an emphasis on operational efficiency also play significant roles in its profitability.

Schwazze Financial Statement Overview

Summary

Medicine Man Technologies is experiencing revenue growth but faces challenges with profitability and financial stability. While the company has positive operating cash flows and improvements in free cash flow, its high leverage and negative net profit margins are significant concerns.

Income Statement

Medicine Man Technologies has shown revenue growth over the years, with a notable increase from 2020 to 2023. However, despite this growth, the company is struggling with profitability as indicated by the negative net income margins across the periods. The EBIT and EBITDA margins have shown some improvement, but the persistent negative net profit margin is a significant concern.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio due to increasing debt levels over the years, which is a risk factor. The equity ratio is relatively stable, but the decreasing stockholder's equity from 2021 to 2023 indicates potential financial instability. The company needs to manage its liabilities more effectively to enhance financial health.

Cash Flow

The cash flow statements reveal positive operating cash flows in recent years, which is a positive sign. There is a noticeable improvement in free cash flow from negative to positive in 2023, indicating better cash management. However, the free cash flow growth has been inconsistent, and the reliance on financing activities in previous years could pose risks.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	174.91M	172.45M	159.38M	108.42M	24.00M	10.62M
Gross Profit	56.31M	76.02M	85.03M	49.35M	6.77M	3.00M
EBITDA	15.16M	38.19M	38.12M	34.51M	-19.80M	-13.40M
Net Income	-59.68M	-34.55M	-18.47M	14.52M	-19.42M	-16.98M
Balance Sheet
Total Assets	339.61M	358.14M	322.92M	285.03M	70.68M	32.23M
Cash, Cash Equivalents and Short-Term Investments	12.39M	19.71M	39.40M	106.40M	1.23M	11.85M
Total Debt	198.19M	191.87M	148.23M	106.33M	21.55M	66.80K
Total Liabilities	248.82M	238.85M	190.76M	151.46M	28.91M	5.65M
Stockholders Equity	90.79M	119.29M	132.16M	133.57M	41.77M	26.58M
Cash Flow
Free Cash Flow	-1.47M	1.59M	-3.42M	51.67M	-10.57M	-7.75M
Operating Cash Flow	6.59M	12.20M	11.39M	57.33M	-9.80M	-7.55M
Investing Cash Flow	-8.06M	-26.44M	-79.18M	-81.16M	-33.22M	-1.12M
Financing Cash Flow	-6.14M	-5.46M	843.81K	129.00M	31.90M	20.20M

Schwazze Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHWZ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 21.38 is Positive, neither overbought nor oversold. The STOCH value of -3.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SHWZ.

Schwazze Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TLRY	49 Neutral	$1.15B	-0.44	-83.42%	―	2.31%	-726.28%
SNDL	48 Neutral	$419.72M	-6.44	-7.82%	―	1.76%	18.31%
IXHL	47 Neutral	$134.58M	-0.35	-114.52%	―	-86.05%	24.17%
SHWZ	45 Neutral	$78.00	―	―	―	―	―
FLGC	43 Neutral	$6.59M	-0.20	-37.38%	―	-22.60%	53.82%
IMCC	40 Underperform	$7.45M	-1.72	-93.87%	―	-0.74%	81.49%

Schwazze Corporate Events

Schwazze Enters Restructuring Agreement with Vireo Growth

On October 10, 2025, Medicine Man Technologies, Inc., operating as Schwazze, entered into a Restructuring Support Agreement (RSA) with Vireo Growth Inc. to restructure its operations and capital structure. This involves the sale of a majority of the company’s assets to a new entity, NewCo, majority-owned by Vireo, and the liquidation of remaining assets. The restructuring aims to create a growth-oriented company with reduced debt and improved liquidity. The RSA outlines a series of transactions, including an asset sale through a public auction, with Vireo submitting a credit bid. The restructuring is expected to extinguish obligations under the Senior Secured Notes and Star Bud Notes, with NewCo receiving up to $62 million in financing for refinancing and working capital. The announcement marks a significant milestone for Schwazze, positioning it for market consolidation opportunities.

The most recent analyst rating on (SHWZ) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Schwazze stock, see the SHWZ Stock Forecast page.